Rapid NCCT Stroke
K222884iSchemaView, Inc. · cleared 2023-03-02 · product code QAS · Radiology
Premarket evidence — what FDA accepted
source quote (p.5)
“Rapid NCCT Stroke (RNS) is a radiological computer-assisted triage and notification software device. RNS is a non-enhanced CT (NCCT) processing module which operates within the integrated Rapid Platform to provide triage and notification prioritization of suspected intracranial Hemorrhage (ICH) and NCCT Large Vessel Occlusion (LVO) of the ICA and MCA-M1. The RNS is an AI/ML SaMD.”
source quote (p.5)
“The RNS is an AI/ML SaMD. The output of the module is a priority notification to clinicians indicating the suspicion of ICH or NCCT LVO. ICH analysis uses the ICH Algorithm to identify findings within the ICH algorithm; and the NCCT LVO suspicion uses the combined analysis of the ASPECTS and Hyperdense Vessel Sign (HVS) algorithms. Technology AI/ML/Neural Network”
Validation studies (1)
Retrospective clinical
n=254 cases
endpoints: software's performance in identifying NCCT head images containing intracranial hemorrhage (ICH); software's performance in identifying NCCT head images containing large vessel occlusion (LVO) findings
standards: EN ISO 14971:2012, IEC 62304:2015, NEMA PS 3.1 - 3.20
Reported performance (26 observations)
source quote (p.9)
“LVO was observed at Se:0.635 (95% CI: 0.544 - 0.717)”
source quote (p.9)
“LVO was observed at ... Sp: 0.951 (95% CI: 0.891 – 0.979).”
source quote (p.9)
“ICH performance was observed at Se:0.962”
source quote (p.9)
“Sp:0.974”
source quote (p.10)
“Sensitivity 57 0.579 0.450 0.698”
source quote (p.10)
“Specificity 54 0.981 0.902 0.997”
source quote (p.10)
“Sensitivity 58 0.690 0.562 0.794”
source quote (p.10)
“Specificity 45 0.933 0.821 0.977”
source quote (p.10)
“Sensitivity 12 0.583 0.320 0.807”
source quote (p.10)
“Specificity 21 0.905 0.711 0.973”
source quote (p.10)
“Sensitivity 41 0.610 0.457 0.743”
source quote (p.10)
“Specificity 42 0.976 0.877 0.996”
source quote (p.10)
“Sensitivity 62 0.661 0.537 0.767”
source quote (p.10)
“Specificity 35 0.971 0.855 0.995”
source quote (p.10)
“Sensitivity 29 0.724 0.543 0.853”
source quote (p.10)
“Specificity 55 0.964 0.877 0.990”
source quote (p.11)
“Sensitivity 86 0.605 0.499 0.701”
source quote (p.11)
“Specificity 48 0.938 0.832 0.979”
source quote (p.11)
“Sensitivity 37 0.730 0.570 0.846”
source quote (p.11)
“Specificity 11 1.000 0.741 1.000”
source quote (p.11)
“Sensitivity 11 0.545 0.280 0.787”
source quote (p.11)
“Specificity 22 1.000 0.851 1.000”
source quote (p.11)
“Sensitivity 32 0.500 0.336 0.664”
source quote (p.11)
“Specificity 59 0.915 0.816 0.963”
source quote (p.11)
“Sensitivity 35 0.686 0.520 0.814”
source quote (p.11)
“Specificity 11 1.000 0.741 1.000”
Each value carries its own analysis unit and task — never compare or pool across devices. Source: 510(k) summary PDF.
Predicate network
Postmarket — what happened after clearance
- re_clearance
The FDA AI/ML device list shows a newer 510(k) K233512 (decision 2024-01-16) from iSchemaView, Inc. for a matching device line ("Rapid (6.0)") — a new clearance for the same line is a change event.
first seen 2026-07-08 · k_number:K233512
Recall and MAUDE counts are product-code-level (reports aren't reliably attributable to one device). Signals are descriptive observables with sources — never a judgment that the device is unsafe or drifting. Snapshot 2026-07-08.
Reimbursement — how devices like this got paid
Not yet tracked — no payment pathway indexed for this clearance (the reimbursement corpus is a growing seed set).